Gilead uses HealthVerity data to find liver-protective treatment
Gilead Sciences ran a retrospective observational cohort study using de-identified EHR and claims data from HealthVerity Marketplace on 3,095 adults with HIV/HBV coinfection who started antiretroviral therapy (ART) between 2016 and early 2024 (76% TAF-based, 13% TDF-based, 11% non-tenofovir-based), tracking liver disease events and enzyme trends for up to five years. TAF-based ART reduced overall liver disease risk by 45% and cirrhosis risk by 58%, and showed a 72% lower risk of hepatocellular carcinoma versus non-tenofovir regimens; TDF-based ART reduced overall risk by 55%. Liver enzymes stayed stable or improved in tenofovir groups but not in the non-tenofovir group.
HealthVerity is a real-world-data marketplace aggregating claims, EHR and lab data from 75+ sources via a proprietary patient-matching layer.
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Published by HealthVerity on its own site — read the original case study on blog.healthverity.com ↗
Related use cases
- 01Symphony Health and dentsu health partner to efficiently reach rare disease patients
- 02Differentiating TYK2 inhibitors with real-world evidence in psoriasis
- 03How HealthVerity Audiences delivered 26.9x targeting precision for a rare kidney disease campaign
- 04Reducing targeting noise by supplementing claims with oncology labs: Metastatic breast cancer case study
- 05Accurately targeting chronic liver disease patients for specialty therapy
- 06Accurately reaching patients with rare hematologic disease